作者采用随机、双盲、安慰剂对照试验研究了口服尼莫地平(Nimodipine)对蛛网膜下腔出血后所致脑梗塞及死亡等严重病变的治疗作用。方法 554例蛛网膜下腔出血病人,在出血后96小时内进行住院治疗。治疗组278例,每4小时口服尼莫地平60mg;对照组276例,口服安慰剂。两组病人年龄、性别、血压,蛛网膜下腔出血严重程度及病史均近似。结果治疗3个月后脑梗塞发病率,治疗组61例(22%),对照组92例(33%)。治 The authors used a randomized, double-blind, placebo-controlled trial of the therapeutic effect of oral nimodipine on severe diseases such as cerebral infarction and death following subarachnoid hemorrhage. Methods 554 patients with subarachnoid hemorrhage were hospitalized within 96 hours after hemorrhage. The treatment group, 278 cases, nimodipine 60mg every 4 hours; control group, 276 cases, oral placebo. Two groups of patients age, gender, blood pressure, subarachnoid hemorrhage severity and history are similar. Results The incidence of cerebral infarction was 3 months after treatment, 61 cases (22%) in treatment group and 92 cases (33%) in control group. rule